Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach

Kidney International

Volumn 79, Issue 5, 2011, Pages 529-537

  Kwon, Hyuk Nam ^a   Kim, Mina ^a   Wen, He ^a   Kang, Sunmi ^a   Yang, Hye Ji ^a   Choi, Myung Joo ^a   Lee, Hee Seung ^a   Choi, Dalwoong ^b   Park, In Suh ^a   Suh, Young Ju ^a   Hong, Soon Sun ^a   Park, Sunghyouk ^a  

^a Inha University Hospital   (South Korea)

^b Korea University   (South Korea)

Author keywords

anticancer; cisplatin; pharmacometabonomics; prediction; toxicity

Indexed keywords

CISPLATIN; CREATININE; DRUG METABOLITE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITROGEN; UREA;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG METABOLISM; HISTOPATHOLOGY; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACOMETABONOMICS; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RAT; SPECTROSCOPY; STATISTICAL TOTAL CORRELATION SPECTROSCOPY; UREA NITROGEN BLOOD LEVEL;

EID: 79951678399     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.440     Document Type: Article

References (62)

1. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009; 112: 275-281.
2. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 2004; 11: 559-595.
3. Smith IE, Talbot DC Cisplatin and its analogues in the treatment of advanced breast cancer: a review. Br J Cancer 1992; 65: 787-793.
4. Crino L, Calandri C, Maestri A et al. Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer. Oncology (Williston Park) 2001; 15: 40-42. (Pubitemid 33739203)
5. Yao X, Panichpisal K, Kurtzman N etal. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007; 334: 115-124. (Pubitemid 47262919)
6. Arany I, Safirstein RL Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464. (Pubitemid 37176691)
7. Vizirianakis IS. Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? Pharmacogenomics 2005; 6: 701-711. (Pubitemid 41479415)
8. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS J 2002; 2: 29-41.
9. Furuta T, Sugimoto M, Shirai N et al. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007; 8: 1199-1210. (Pubitemid 47578229)
10. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and 'individualized drug therapy': high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361-370. (Pubitemid 38044275)
11. Arnett DK, Claas SA, Lynch AI. Has pharmacogenetics brought us closer to 'personalized medicine'for initial drug treatment of hypertension? Curr Opin Cardiol 2009; 24: 333.
12. Ikediobi ON, Shin J, Nussbaum RL et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther 2009; 86: 28-31.
13. Oldenburg J, Fossa SD, Ikdahl T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 2008; 9: 1521-1530.
14. Huang RS, Duan S, Shukla SJ et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007; 81: 427-437. (Pubitemid 47330203)
15. Dawood S, Leyland-Jones B. Pharmacology and pharmacogenetics of chemotherapeutic agents. Cancer Invest 2009; 27: 482-488.
16. Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440: 1073-1077.
17. Schnackenberg LK. Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century. Expert Rev Mol Diagn 2007; 7: 247-259. (Pubitemid 46798615)
18. Li H, Ni Y, Su M et al. Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. J Proteome Res 2007; 6: 1364-1370. (Pubitemid 46724033)
19. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009; 106: 14728-14733.
20. Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci USA 2009; 106: 14187-14188.
21. Nebert DW, Vesell ES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci 2006; 27: 580-586. (Pubitemid 44604301)
22. Ala-Korpela M. Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool. Expert Rev Mol Diagn 2007; 7: 761-773. (Pubitemid 350171839)
23. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res 2006; 23: 1075-1088. (Pubitemid 43946133)
24. Wang EJ, Snyder RD, Fielden MR et al. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 2008; 246: 91-100.
25. Portilla D, Li S, Nagothu KK et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006; 69: 2194-2204. (Pubitemid 43882106)
26. Morvan D, Demidem A. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 2007; 67: 2150-2159. (Pubitemid 46424234)
27. Kim K, Aronov P, Zakharkin SO et al. Urine metabolomic analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009; 8: 558-570.
28. Nicholson JK, Connelly J, Lindon JC et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1: 153-161. (Pubitemid 41646523)
29. Niemann CU, Serkova NJ. Biochemical mechanisms of nephrotoxicity: application for metabolomics. Expert Opin Drug Metab Toxicol 2007; 3: 527-544. (Pubitemid 351324962)
30. Wishart DS. Metabolomics in monitoring kidney transplants. Curr Opin Nephrol Hypertens 2006; 15: 637-642. (Pubitemid 44607437)
31. Cloarec O, Dumas ME, Craig A et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 2005; 77: 1282-1289. (Pubitemid 40327865)
32. Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 2010; 243: 154-166.
33. Sieber M, Hoffmann D, Adler M et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol Sci 2009; 109: 336-349.
34. Xie G, Zheng X, Qi X et al. Metabonomic evaluation of melamine-induced acute renal toxicity in rats. J Proteome Res 2010; 9: 125-133.
35. Serkova N, Fuller TF, Klawitter J et al. H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 2005; 67: 1142-1151. (Pubitemid 41623341)
36. Wei L, Liao P, Wu H et al. Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Toxicol Appl Pharmacol 2009; 234: 314-325.
37. Kang J, Choi MY, Kang S et al. Application of a 1H nuclear magnetic resonance (NMR) metabolomics approach combined with orthogonal projections to latent structure-discriminant analysis as an efficient tool for discriminating between Korean and Chinese herbal medicines. J Agric Food Chem 2008; 56: 11589-11595.
38. Wiklund S, Johansson E, Sjostrom L et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008; 80: 115-122. (Pubitemid 351448411)
39. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom 2002; 16: 119-128.
40. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320. (Pubitemid 41130944)
41. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279. (Pubitemid 37487159)
42. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001; 67: 93-130. (Pubitemid 33804642)
43. Santos NAG, Cato CS, Martins NM et al. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch toxicol 2007; 81: 495-504. (Pubitemid 47012464)
44. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007. (Pubitemid 351543900)
45. Bellomo G, Martino A, Richelmi P et al. Pyridine-nucleotide oxidation, Ca2+ cycling and membrane damage during tert-butyl hydroperoxide metabolism by rat-liver mitochondria. Eur J Biochem 1984; 140: 1-6. (Pubitemid 14132041)
46. Jocelyn PC The reduction of diamide by rat liver mitochondria and the role of glutathione. Biochem J 1978; 176: 649-664. (Pubitemid 9090445)
47. Hoek JB, Rydstrom J. Physiological roles of nicotinamide nucleotide transhydrogenase. Biochem J 1988; 254: 1-10.
48. Kand'ar R, Zakova P. Allantoin as a marker of oxidative stress in human erythrocytes. Clin Chem Lab Med 2008; 46: 1270-1274.
49. Jiang G, Yang F, Li M et al. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. Cancer Biol Ther 2003; 2: 103-108.
50. Reddy GK. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2005; 7: 163-165. (Pubitemid 43279862)
51. Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473; discussion 473-475.
52. Gion M, Mione R, Leon AE et al. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem 1999; 45: 630-637. (Pubitemid 29220324)
53. Bast Jr RC, Ravdin P, Hayes DF et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Societyof Clinical Oncology. J Clin Oncol2001; 19: 1865-1878. (Pubitemid 32230890)
54. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. J AmA 1999; 281: 1591-1597. (Pubitemid 29211767)
55. Kang J, Lee S, Kang S et al. NMR-based metabolomics approach for the differentiation of ginseng (Panax ginseng) roots from different origins. Arch Pharm Res 2008; 31: 330-336.
56. Wen H, Yoo SS, Kang J et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol 2010; 52: 228-233.
57. Tomasi G, van den Berg F, Andersson C Correlation optimized warping and dynamic time warping as preprocessing methods for chromatographic data. J Chemometr 2004; 18: 231-241.
58. Bylesjo M, Rantalainen M, Cloarec O et al. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom 2006; 20: 341-351.
59. Couto Alves A, Rantalainen M, Holmes E et al. Analytic properties of statistical total correlation spectroscopy based information recovery in (1)H NMR metabolic data sets. Anal Chem 2009; 81: 2075-2084.
60. Sands CJ, Coen M, Maher AD et al. Statistical total correlation spectroscopy editing of 1H NMR spectra of biofluids: application to drug metabolite profile identification and enhanced information recovery. Anal Chem 2009; 81: 6458-6466.
61. Maher AD, Cloarec O, Patki P et al. Dynamic biochemical information recovery in spontaneous human seminal fluid reactions via 1H NMR kinetic statistical total correlation spectroscopy. Anal Chem 2009; 81: 288-295.
62. Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8: 1439-1444. (Pubitemid 36019430)